Over the weekend, after reviewing the data by three independent groups of scientists, the 68% efficacy of ivermectin as a preventative against deaths caused by COVID-19 was confirmed. The final results of the peer-reviewed study were published in the prestigious scientific journal Cureus.
Cureus has two esteemed editors-in-chief in the scientific community: Dr John Adler Jr, Professor of Neurosurgery and Radiation Oncology (Emeritus) at Stanford University in California, and Dr Alexander Muacevic, the medical director of the European Radiosurgery Center in Munich, Germany and a professor at the University of Munich Hospitals.
“In addition to peer review, the study goes through three editorial stages. And all three need to accept the work. In our case, due to the relevance of the study, we didn’t even have the opportunity to appoint reviewers. All were completely independent,” said Dr. Flavio Cadegiani, one of the scientists involved in the data analysis.
